ASH 2022 Conference Coverage
ASH 2022 Results of the ASCENT Trial: Fixed Duration Therapy With Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for High-Risk Smoldering MM
By
ASH 2022 Conference Coverage
FEATURING
Shaji Kumar
By
ASH 2022 Conference Coverage
FEATURING
Shaji Kumar
Login to view comments.
Click here to Login